Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19

References

• World Health Organization. COVID-19 weekly epidemiological update; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update—2-march-2021. Accessed March 04, 2021.
   Google Scholar
• CDC. Older adults; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html. Accessed March 18, 2021.
   Google Scholar
• CDC. COVID-19 hospitalization and death by age; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html. Accessed August 11, 2020.
   Google Scholar
• Schwartz M, Emerson S, Punt J, Goff WJA. Decreased Naïve T-cell production leading to cytokine storm as cause of increased COVID-19 severity with comorbidities. Aging Dis. 2020;11(4):742–745. doi:10.14336/AD.2020.0619
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley D, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
   PubMed Web of Science ®Google Scholar
• Droesch C, Hoang M, DeSancho M, Lee E, Magro C, Harp J. Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19. JAMA Dermatol. 2020;156:1. doi:10.1001/jamadermatol.2020.2800
   PubMed Web of Science ®Google Scholar
• Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kong W, Xia P, et al. Impaired fasting glucose and diabetes are related to higher risks of complications and mortality among patients with coronavirus disease 2019. Front Endocrinol. 2020;11:525.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI137244
   PubMed Web of Science ®Google Scholar
• Laterre P, François B, Collienne C, et al. Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19). JAMA Network Open. 2020;3(7):e2016485. doi:10.1001/jamanetworkopen.2020.16485
   PubMed Web of Science ®Google Scholar
• Chang D, Zhao P, Zhang D, et al. Persistent viral presence determines the clinical course of the disease in COVID-19. J Allergy Clin Immunol. 2020.
   Web of Science ®Google Scholar
• Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020;11(1):3774.
   PubMed Web of Science ®Google Scholar
• Carvelli J, Demaria O, Vély F, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323(11):1092–1093. doi:10.1001/jama.2020.1623
   PubMed Web of Science ®Google Scholar
• Laforge M, Elbim C, Frère C, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020;20:515–516. doi:10.1038/s41577-020-0407-1
   PubMed Web of Science ®Google Scholar
• Pence BJG. Severe COVID-19 and aging: are monocytes the key? GeroSci. 2020;42(4):1051–1061.
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. doi:10.1038/s41591-020-0901-9
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi:10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Duijf P. Baseline pulmonary levels of CD8+ T cells and NK cells inversely correlate with expression of the SARS-CoV-2 entry receptor ACE2. BioRxiv. 2020.
   PubMedGoogle Scholar
• Du R, Liang L, Yang C, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5). doi:10.1183/13993003.00524-2020.
   Web of Science ®Google Scholar
• Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not a cytokine storm characterize COVID-19 infections. JCI Insight. 2020;5. doi:10.1172/jci.insight.140329
   PubMed Web of Science ®Google Scholar
• Argyropoulos KV, Serrano A, Hu J, et al. Withdrawn: association of initial viral load in SARS-CoV-2 patient with outcome and symptoms. Am J Pathol. 2020.
   Web of Science ®Google Scholar
• Liu Y, Yan L-M, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656–657. doi:10.1016/S1473-3099(20)30232-2
   PubMed Web of Science ®Google Scholar
• Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;369:m1443.
   PubMed Web of Science ®Google Scholar
• Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12(11):1301–1309. doi:10.1038/nm1492
   PubMed Web of Science ®Google Scholar
• Liu J, Hill B, Darko S, et al. The peripheral differentiation of human natural killer T cells. Immunol Cell Biol. 2019;97(6):586–596.
   PubMed Web of Science ®Google Scholar
• Ren L, Zhang L, Chang D, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol. 2020.
   Web of Science ®Google Scholar
• Shankar EM, Che KF, Yong YK, et al. Asymptomatic SARS-CoV-2 infection: is it all about being refractile to innate immune sensing of viral spare-parts?—Clues from exotic animal reservoirs. Pathog Dis. 2021;79(1):ftaa076. doi:10.1093/femspd/ftaa076
   PubMed Web of Science ®Google Scholar
• Sharma L, Chang D, Cruz CSD. Does inflammation help during COVID-19? ERJ Open Res. 2020;6(4):00557–2020. doi:10.1183/23120541.00557-2020
   PubMedGoogle Scholar
• Girija A, Shankar EM, Larsson M. Could SARS-CoV-2-induced hyperinflammation magnify the severity of coronavirus disease (CoViD-19) leading to acute respiratory distress syndrome? Front Immunol. 2020;11:1206. doi:10.3389/fimmu.2020.01206
   PubMed Web of Science ®Google Scholar
• Group RC. Dexamethasone in hospitalized patients with Covid-19—preliminary report. New England J Med. 2020.
   Web of Science ®Google Scholar
• Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:1–13. doi:10.1186/s13293-020-00304-9
   PubMed Web of Science ®Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar